Meeting
2019 Genitourinary Cancers Symposium
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
Authors
Rebeca Lozano
Spanish National Cancer Research Centre, Madrid, Spain
Rebeca Lozano , Elena Castro , Josep M. Piulats , Ana Medina , Jose Carlos Villa Guzman , Iciar Garcia Carbonero , Rosa Villatoro , Jose Angel Arranz , Jose Luis Perez-Gracia , Javier Garde , Aranzazu Gonzalez del Alba , A. Montesa , Raquel Luque , Pablo Borrega , Sergio Vázquez , Esther Martinez , Belen Gonzalez Gragera , Nuria Romero-Laorden , David Olmos , David Lorente
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 264)
DOI
10.1200/JCO.2019.37.7_suppl.264
Abstract #
264
Poster Bd #
L21
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.
First Author: Maria Jose Mendez-Vidal
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa
Poster
2020 Genitourinary Cancers Symposium
Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.
First Author: Orazio Caffo